NCPI
NIH Cloud PlatformInteroperability Effort
searchclose
YouYube

Study

arrow_backDatasets

NHLBI TOPMed: Childhood Asthma Management Program (CAMP)

phs001726.v1.p1dbGapdbGap FHIR

Description

The Childhood Asthma Management Program (CAMP) was designed to evaluate whether continuous, long-term treatment (over a period of four to six years) with either an inhaled corticosteroid (budesonide) or an inhaled noncorticosteroid drug (nedocromil) safely produces an improvement in lung growth as compared with treatment for symptoms only (with albuterol and, if necessary, prednisone, administered as needed). The primary outcome in the study was lung growth, as assessed by the change in forced expiratory volume in one second (FEV1, expressed as a percentage of the predicted value) after the administration of a bronchodilator. Secondary outcomes included the degree of airway responsiveness, morbidity, physical growth, and psychological development.

Summary

PlatformsBDC
Consent CodesDS-AST-COPD
Focus / DiseasesAsthma
Study DesignFamily/Twin/Trios
Data TypesSNP/CNV Genotypes (NGS), WGS
Subjects2,290